ARE-I polymorphism on PSA gene in prostate cancer patients of a turkish population

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1395-1398

  Kalay, Ebru ^a   Ergen, Arzu ^a   Narter, Fehmi ^a,b   Aǧachan, Bedia ^a   Görmtüş, Uzay ^a   Yiǧit, Nilüfer ^a   Isbir, Turgay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Uskudar State Hospital   (Turkey)

Author keywords

ARE I; Polymorphism; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYMATIC ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

AGED; ANDROGENS; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESPONSE ELEMENTS; TURKEY;

EID: 64949127020     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Neal DE, Leung HY, Powell PH, Hamdy FC and Donovan JL: Unanswered questions in screening for prostate cancer. Eur J Cancer 36: 1316-1321,2000.
2. Steinberg GD, Carter BS, Beaty TH, Childs B and Walsh PC: Family history and the risk of prostate cancer. Prostate 17(4): 337-347, 1990.
3. Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22(4): 232-240, 1972.
4. Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H et al: Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 92(5): 683-686, 2001.
5. Steers WD: 5Alpha-reductase activity in the prostate. Urology 58(6Suppl 1): 17-24,2001.
6. Homma Y, Kaneko M, Kondo Y, Kawabe K and Kakizoe T: Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143. J Natl Cancer Inst 89(11): 803-807, 1997.
7. Mulay K, Swain M, Jaiman S and Gowrishankar S: Gleason scoring of prostatic carcinoma: impact of a web-based tutorial on inter-and intra-observer variability. Indian J Pathol Microbiol 51(1): 22-25, 2008.
8. Wang LZ, Satoa K, Tsuchiyaa N, Yua JG, Ohyamaa C, Satoha S et al: Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Let 202: 53-59, 2003.
9. Kim J and Coetzee GA: Prostate-specific antigen gene regulation by androgen receptor. J of Cell Biochem 93: 233-241, 2004.
10. Diamandis EP and Yousef GM: Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Expert Rev Mol Diagn 1(2): 182-190, 2001.
11. Xu J, Meyers DA, Sterling DA, Zheng SL, Catalona WJ, Cramer SD et al: Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol, Biomarkers Prev 11: 664-669, 2002.
12. Lee DK and Chang C: Molecular communication between androgen receptor and general transcription machinery. J Steroid Biochem Mol Biol 84: 41-49, 2003.
13. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN et al: Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 95(14): 1027-1028, 2003.
14. Gsur A, Preyer M, Haidinger G, Zidek T, Madersbacher S, Schatzl G et al: Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23(10): 1647-1651, 2002.
15. Balk SP, Ko YJ and Bubley GJ: Biology of prostate-specific antigen. J Clin Oncol 21(2): 383-391, 2003.
16. Xue WM, Coetzee G, Ross R, Irvine R, Kolonel L, Henderson B et al: Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 10: 575-579, 2001.
17. Coughlin SS and Hall GJ: A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 12: 182-196, 2002.
18. Schuur E, Henderson G, Kmetec L, Miller J, Lamparski H and Henderson D: Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271: 7043-7051, 1996.
19. Yeung F, Li X, Ellett J, Trapmani J, Kao C and Chung LWK: Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 275(52): 40846-40855, 2000.
20. Cleutjens KB, Van Der Korput HA, Van Eekelen CC, Van Rooij HC, Faber PW and Trapman J: An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen. Mol Endocrinol 11: 148-161, 1997.
21. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D and Oliveira J: Linkage between polymorphisms in the prostate-specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 53: 88-94, 2002.
22. Schatzl G, Madersbacher S, Gsur A, Preyer M, Haidinger G, Haitel A et al: Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate 52(2): 130-138,2002.
23. Rao A, Chang B, Hawkins G, Hu J, Rosser CJ, Hall MC et al: Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology 61: 864-869, 2003.
24. Dos Santos RM, De Jesus CM, Filho JC, Trindade JC, De Camargo JL, Rainho CA et al: PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy. DNA Cell Biol 27: 1-7, 2008.
25. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA and Ingles SA: Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60: 839-841, 2000.
26. Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, Spurdle AB et al: PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 2S(5):1032-1039, 2007.